Scientific Publications

SphingoTec's biomarker discovery is based on the highest standard of evidence, with over 100 publications, over 100 clinical studies, and more than 100.000 patients enrolled. Browse our scientific publications to learn more about how our biomarkers can impact patient care. You can use filters to narrow your search results by Year, Biomarker and Indications.

2023 bio-ADM penKid Major Surgery Other

View the paper

2023 bio-ADM Major Surgery Other

View the paper

2023 bio-ADM penKid Major Surgery

View the paper

2022 bio-ADM Cardiovascular Disease Major Surgery

View the paper

2020 penKid Acute Kidney Injury Major Surgery

View the paper

2020 bio-ADM Major Surgery

View the paper

2020 DPP3 Major Surgery

View the paper

2017 penKid Major Surgery

View the paper

Scientific Publications

Filter

Proenkephalin A and bioactive adrenomedullin are useful for risk prognostication in cardiac surgery

Bioactive adrenomedullin (bio-ADM) is associated with endothelial dysfunction in infants and children with complex congenital heart disease undergoing open-heart surgery on cardiopulmonary bypass

Proenkephalin A and bioactive adrenomedullin are useful for risk prognostication in cardiac surgery

The value of bioactive adrenomedullin and dipeptidyl peptidase 3 to predict short-term unfavorable outcomes after cardiac surgery.

Proenkephalin A 119-159 may predict post-operative acute kidney injury and in hospital mortality following open or endovascular thoraco-abdominal aortic repair

Postoperatively increased bioactive adrenomedullin is related to adverse outcome after complex aortic surgery

In-hospital mortality and organ failure after open and endovascular thoraco-abdominal aortic surgery can be predicted by increased levels of circulating dipeptidyl peptidase 3

Elevated soluble urokinase plasminogen activator receptor and proenkephalin serum levels predict the development of acute kidney injury after cardiac surgery